CARDINAL HEALTH INC CAH

Industrials SIC 5122 - Wholesale-Drugs, Proprietaries & Druggists' Sundries NAICS Wholesale Trade › Merchant Wholesalers, Nondurable Goods › Drugs and Druggists' Sundries Merchant Wholesalers derived NYSE

Last close 249.57 2026-10-23
Market cap $58.04B 2026-06-30 share count
52-week range 161.35 - 259.21

Valuation FY2026 figures against the last close

P/S0.2x
P/E34.5x
P/FCF12.8x
EV/EBITDA16.3x
Dividend yield0.8%
Diluted EPS7.23

Annual financial statements

Income statement

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $254.25B$222.58B$226.83B$204.98B$181.33B$162.47B$152.92B$145.53B$136.81B$129.98B
Cost of revenue $244.47B$214.41B$219.41B$198.10B$174.84B$155.69B$146.05B$138.70B$129.63B$123.43B
Gross profit $9.77B$8.17B$7.41B$6.87B$6.48B$6.78B$6.87B$6.83B$7.18B$6.54B
SG&A $6.13B$5.38B$5.00B$4.80B$4.51B$4.53B$4.57B$4.48B$4.60B$3.77B
Operating income $2.61B$2.27B$1.24B$752.0M-$607.0M$472.0M-$4.10B$2.06B$126.0M$2.12B
Interest expense $348.0M$215.0M$51.0M$84.0M$147.0M$180.0M$238.0M$294.0M$329.0M$201.0M
Pre-tax income $2.17B$2.10B$1.20B$663.0M-$784.0M$323.0M-$3.77B$1.75B-$228.0M$1.92B
Income tax $469.0M$532.0M$348.0M$332.0M$153.0M$289.0M$79.0M$386.0M$487.0M$630.0M
Net income $1.71B$1.56B$852.0M$330.0M-$938.0M$611.0M-$3.70B$1.36B$256.0M$1.29B
EPS, basic 7.276.483.481.27-3.372.09-12.614.550.824.06
EPS, diluted 7.236.453.451.26-3.372.08-12.614.530.814.03
Shares, diluted (wtd. avg.) 237.0M242.0M247.0M262.0M279.0M294.0M293.0M301.0M315.0M320.0M

Balance sheet

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $4.86B$3.87B$5.13B$4.08B$4.75B$3.38B$2.77B$2.53B$1.76B$6.88B
Short-term investments ——$200.0M———————
Receivables $13.81B$13.24B$12.08B$11.11B$10.56B$9.10B$8.26B$8.45B$7.80B$8.05B
Inventory $17.30B$16.83B$14.96B$16.12B$15.64B$14.59B$13.20B$12.82B$12.31B$11.30B
Total current assets $38.75B$36.37B$34.88B$33.74B$32.94B$31.05B$25.94B$25.75B$24.55B$28.34B
Property, plant and equipment $3.03B$2.86B$2.53B$2.46B$2.36B$2.36B$2.37B$2.36B$2.49B$1.88B
Goodwill $11.44B$9.69B$4.72B$4.61B$5.86B$7.99B$8.36B$8.38B$8.32B$7.22B
Other intangibles $2.19B$2.49B$1.73B$1.47B$1.77B$2.10B$2.92B$3.43B$3.91B$1.99B
Total assets $57.30B$53.12B$45.12B$43.35B$43.88B$44.45B$40.77B$40.96B$39.95B$40.11B
Accounts payable $38.28B$34.71B$31.76B$29.93B$27.13B$23.70B$21.37B$21.54B$19.68B$17.91B
Total current liabilities $43.90B$38.90B$35.64B$33.74B$30.55B$27.62B$23.61B$24.11B$22.89B$21.22B
Retained earnings $2.01B$783.0M-$286.0M-$642.0M-$280.0M$1.21B$1.17B$5.43B$4.64B$4.97B
Total equity -$2.88B-$2.78B-$3.21B-$2.96B-$882.0M$1.62B$1.79B$6.33B$6.06B$6.83B

Cash flow

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $5.17B$2.40B$3.76B$2.84B$3.17B$2.43B$1.96B$2.72B$2.77B$1.18B
Depreciation and amortisation $956.0M$790.0M$710.0M$692.0M$692.0M$783.0M$913.0M$1.00B$1.03B$717.0M
Stock-based compensation $367.0M$244.0M$121.0M$96.0M$81.0M$89.0M$90.0M$82.0M$85.0M$96.0M
Capital expenditure $649.0M$547.0M$511.0M$481.0M$387.0M$400.0M$375.0M$328.0M$384.0M$387.0M
Investing cash flow -$2.58B-$5.59B-$1.85B-$454.0M$567.0M-$378.0M$493.0M$338.0M-$5.61B-$405.0M
Financing cash flow -$1.60B$1.94B-$847.0M-$3.05B-$2.46B-$1.32B-$2.20B-$2.29B-$2.28B$3.75B
Dividends paid $491.0M$494.0M$499.0M$525.0M$559.0M$573.0M$569.0M$577.0M$581.0M$577.0M
Buybacks $1.36B$765.0M$750.0M$2.00B$1.00B$200.0M$350.0M$600.0M$550.0M$600.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000721371-26-000038.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -100B 0 100B 200B 300B Revenue, FY2017: 130B Gross profit, FY2017: 6.5B Net income, FY2017: 1.3B Revenue, FY2018: 136.8B Gross profit, FY2018: 7.2B Net income, FY2018: 256M Revenue, FY2019: 145.5B Gross profit, FY2019: 6.8B Net income, FY2019: 1.4B Revenue, FY2020: 152.9B Gross profit, FY2020: 6.9B Net income, FY2020: -3.7B Revenue, FY2021: 162.5B Gross profit, FY2021: 6.8B Net income, FY2021: 611M Revenue, FY2022: 181.3B Gross profit, FY2022: 6.5B Net income, FY2022: -938M Revenue, FY2023: 205B Gross profit, FY2023: 6.9B Net income, FY2023: 330M Revenue, FY2024: 226.8B Gross profit, FY2024: 7.4B Net income, FY2024: 852M Revenue, FY2025: 222.6B Gross profit, FY2025: 8.2B Net income, FY2025: 1.6B Revenue, FY2026: 254.2B Gross profit, FY2026: 9.8B Net income, FY2026: 1.7B FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue $129.98B $136.81B $145.53B $152.92B $162.47B $181.33B $204.98B $226.83B $222.58B $254.25B
Gross profit $6.54B $7.18B $6.83B $6.87B $6.78B $6.48B $6.87B $7.41B $8.17B $9.77B
Net income $1.29B $256.0M $1.36B -$3.70B $611.0M -$938.0M $330.0M $852.0M $1.56B $1.71B

Recent filings and events

  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 5122

TickerCompanyMarket capP/ERevenue growth
MCK MCKESSON CORP $116.68B 26.1x 12.4%
COR Cencora, Inc. $63.16B 41.6x 9.3%
HLF HERBALIFE LTD. $1.40B 6.1x 0.9%
NUS NU SKIN ENTERPRISES, INC. $233.2M 1.5x -14.3%
COSM Cosmos Health Inc. $26.3M — 19.9%
HWH HWH International Inc. $20.7M — -30.8%
MEDS DataMeds AI, Inc. $6.8M — 28.7%
HKPD Cellyan Biotechnology Co., Ltd — — —